Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS · Delayed Price · Currency is USD
2.000
-0.040 (-1.96%)
Feb 12, 2026, 1:39 PM EST

Medexus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21
Net Income
-0.272.25-0.211.22-2.88-28.26
Depreciation & Amortization
9.717.185.816.086.145.98
Other Amortization
----00
Asset Writedown & Restructuring Costs
0.342.80.89-1.75-
Stock-Based Compensation
0.160.410.471.221.881.27
Other Operating Activities
3.085.559.425.3-12.8125.88
Change in Accounts Receivable
2.4110.54-1.68-8.244.43-3.51
Change in Inventory
2.9-4.6-6.75-1.99-6.66-0.01
Change in Accounts Payable
3.66-1.998.584.753.614.63
Change in Other Net Operating Assets
-4.221.92.19-9.793.36-0.93
Operating Cash Flow
17.3624.0318.71-1.44-1.185.04
Operating Cash Flow Growth
-25.69%28.43%----
Capital Expenditures
-0.2-0.18-0.05-0.06-0.1-0.12
Cash Acquisitions
-4.43-3.28-3.21-1.36-0.48-0.95
Sale (Purchase) of Intangibles
-7.5-2.54-0.22-0.3-7.62-10.64
Investing Cash Flow
-11.49-6-3.48-1.72-8.2-11.71
Long-Term Debt Issued
--17.5835.463.890.35
Long-Term Debt Repaid
--14.24-43.99-24.72-0.16-0.37
Net Debt Issued (Repaid)
-16.03-14.24-26.410.733.73-0.02
Issuance of Common Stock
19.319.37.61--22.64
Repurchase of Common Stock
-0.38-----
Other Financing Activities
-2.48-4.27-4.25-4.33-3.07-3.93
Financing Cash Flow
0.420.8-23.056.410.6618.68
Foreign Exchange Rate Adjustments
0.24-0.11-0-0.190.031.45
Net Cash Flow
6.5318.72-7.813.05-8.6913.47
Free Cash Flow
17.1623.8518.66-1.51-1.284.92
Free Cash Flow Growth
-26.14%27.79%----
Free Cash Flow Margin
17.26%22.02%16.51%-1.39%-1.67%6.18%
Free Cash Flow Per Share
0.540.900.84-0.07-0.060.32
Cash Interest Paid
2.484.274.254.333.073.64
Cash Income Tax Paid
0.220.221.420.910.680.87
Levered Free Cash Flow
11.3928.328.47-8.98-10.18-8.96
Unlevered Free Cash Flow
15.2533.4416.83-0.48-2.54-2.82
Change in Working Capital
4.765.842.34-15.264.730.18
Source: S&P Global Market Intelligence. Standard template. Financial Sources.